12:00 AM
May 06, 2013
 |  BC Week In Review  |  Company News  |  Deals

Heptares, Takeda deal

Heptares received a £1 million ($1.5 million) payment for achieving all research milestones under a 2011 deal with Takeda to develop compounds against GPCR to treat schizophrenia. Heptares used its structure-based drug...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >